A phase I clinical trial with patients with r/r non-Hodgkin lymphoma (NHL) showed that autologous CD19/CD20 bispecific CAR-T cell therapy was safe and demonstrated strong efficacy (90% ORR, 70% CR rate) [22]. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.